Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients

Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly observed. All clinical stage PIs effectively inhibit chymotrypsin‐like (CT‐L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase‐like (C‐L) and trypsin‐like (T‐L)...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Nancy, Spencer, Andrew, Harrison, Simon J., Chauhan, Dharminder, Burrows, Francis J., Anderson, Kenneth C., Reich, Steven D., Richardson, Paul G., Trikha, Mohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084787/
https://www.ncbi.nlm.nih.gov/pubmed/27161872
http://dx.doi.org/10.1111/bjh.14113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084787/
https://www.ncbi.nlm.nih.gov/pubmed/27161872
http://dx.doi.org/10.1111/bjh.14113

Ejemplares similares